Evidence map›Paper›PMID 28791489›Full record

ArticleBreast cancer research and treatment2017

Metalloprotease-dependent activation of EGFR modulates CD44

Randi Wise, Anna Zolkiewska

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Article
  13. Article
  14. Cellular Plasticity in Breast Cancer Progression and Therapy.Frontiers in molecular biosciences · 2020
    Review
  15. Expression of cancer stem cell markers in breast phyllodes tumor.Cancer biomarkers : section A of Disease markers · 2020
    Article
  16. HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  17. Anticancer Activities ofInternational journal of molecular sciences · 2019
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Randi WiseDepartment of Biochemistry and Molecular Biophysics, Kansas State University, 141 Chalmers Hall, Manhattan, KS, 66506, USA.
Anna ZolkiewskaDepartment of Biochemistry and Molecular Biophysics, Kansas State University, 141 Chalmers Hall, Manhattan, KS, 66506, USA. zolkiea@ksu.edu.ORCID http://orcid.org/0000-0003-3632-9337
Kansas State University · US

Funding

ADAM12 in Breast Tumor Initiating CellsR01CA172222 · NCI · KANSAS STATE UNIVERSITY · PI ZOLKIEWSKA, ANNA · 2013 to 2016
$1.2M
NCI NIH HHS R01 CA172222
6 · The paper itself

Abstract

purposeThe CD44

methodsRepresentative TNBC cell lines SUM159PT (claudin-low) and SUM149PT (basal) were used to evaluate cell surface expression of CD44 and CD24 by flow cytometry in response to EGFR and MEK inhibition or activation. EGFR and ERK phosphorylation levels were analyzed by Western blotting. The relationship between EGFR phosphorylation and MEK activation score in basal and claudin-low tumors from the TCGA database was examined.

resultsInhibition of ERK activation with selumetinib, a MEK1/2 inhibitor, blocked EGF-induced expansion of CD44

conclusionOur results demonstrate that ERK activation is a key event in EGFR-dependent regulation of CD44

Indexed as

BenzimidazolesCD24 AntigenCell Line, TumorDatabases, GeneticDual-Specificity PhosphatasesErbB ReceptorsErlotinib HydrochlorideExtracellular Signal-Regulated MAP KinasesFemaleGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsMitogen-Activated Protein Kinase PhosphatasesPhenylalaninePhosphorylationThiophenesAZD 6244batimastatBenzimidazolesCD24 AntigenCD24 protein, humanCD44 protein, humanDual-Specificity PhosphatasesDUSP4 protein, humanEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideExtracellular Signal-Regulated MAP KinasesHyaluronan ReceptorsMitogen-Activated Protein Kinase PhosphatasesPhenylalanineThiophenesBreast cancerCancer stem cellsCD24CD44Epidermal growth factor receptorMetalloproteasesMitogen-activated protein kinase pathway

Identifiers

PMID28791489
PMCPMC5669811
OpenAlexW2742453621

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.